AUTHORS
Michelle Worst, PharmD, BCOP, MBA, CHCP, Sarah Elizabeth Bomba, PharmD, BCOP2, Heather P. Friedman, MPH3, John O. Mascarenhas, MD4
AFFILIATIONS
1 Medscape LLC, Newark, New Jersey, United States
2 Medscape LLC, Newark, New Jersey, United States
3 Medscape LLC, Newark, New Jersey, United States
4 Tish Cancer Institute, New York, New York, United States
ABSTRACT
Background: Myelofibrosis (MF) is a chronic myeloproliferative neoplasm that requires individualized, evidence-based management to optimize patient outcomes and quality of life. As new insights into disease biology and treatment continue to emerge, clinicians must integrate evolving evidence with guideline-recommended care to inform therapeutic decision-making. Continuing medical education (CME) can help address educational gaps by strengthening clinicians' understanding of MF pathobiology, improving application of evidence-based management strategies, and increasing confidence in delivering person-centered care. This study assessed the educational impact of a multidisciplinary CME activity on clinicians' knowledge, competence, and confidence related to evidence-based management of patients with MF.
Methods Educational outcomes were evaluated following a 73-minute, CME-certified online enduring activity from a live symposium presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. Impact was assessed using matched pre-/post-assessments with multiple-choice questions developed and reviewed by subject matter experts. Data from hematologists, nurse practitioners (NPs), nurses, and pharmacists who completed both pre- and post-activity assessments were included and analyzed in aggregate. Relative changes in percentage of correct responses were used to measure improvement by clinical theme. A McNemar test assessed significant levels of changes reported, with P values < .05 considered statistically significant. The activity launched on June 20, 2025, with data collected through July 2026.
Results: The full analysis included 3,733 clinicians. Educational gains were observed across key domains of MF management, with the greatest improvements seen in areas requiring application of evolving evidence and clinical guidelines.
Understanding of MF biology and therapeutic approaches demonstrated the highest baseline knowledge among clinicians and further improved following education (42% to 48%; 14% relative improvement; P<.001)
Knowledge of current standards of care represented the largest persistent educational gap, with significant improvement following the activity (16% to 24%; 50% relative improvement; P<.001)
Ability to apply evidence-based practice guidelines to MF management showed the greatest relative improvement after education (19% to 34%; 79% relative improvement; P<.001)
Conclusions: This multidisciplinary CME activity demonstrated meaningful improvements in clinicians’ ability to apply evidence-based approaches to the management of patients with MF. While knowledge of MF mechanisms and available therapies was comparatively higher at baseline, gaps remained in recognition of contemporary standards of care and application of clinical practice guidelines. Significant improvements in these areas suggest that targeted education can effectively support clinicians in translating evolving evidence into clinical practice. These findings reinforce the value of multidisciplinary CME as a strategy to enhance clinician preparedness, strengthen guideline-based decision-making, and promote high-quality, person-centered care for patients with MF.
DISCLOSURES
Sarah Elizabeth Bomba, PharmD, BCOP: No relevant conflicts of interest to declare.